Theramir Ltd

Theramir Ltd is a biopharmaceutical company that is focused on the development of novel microRNA-based therapeutics and companion diagnostics for patients and healthcare providers. Founded in 2016 and headquartered in Cyprus, Theramir’s proprietary technologies are centered around microRNAs (miRNAs), a class of small non-coding RNAs capable of regulating multiple genes and pathways associated with cancer growth and metastasis. The company has successfully developed a panel of miRNAs, both biological and synthetic, which can affect the function and disrupt the expression of an expanding list of oncoproteins that are dysregulated in most cancer types.

Thus, Theramir's technologies have the potential to revolutionize the precision oncology field by creating new knowledge on the pathology of the disease and enabling the customization and personalization of cancer treatment. With a focus on the biopharma, biotechnology, and pharmaceutical industries, Theramir presents an exciting opportunity for investors looking to support groundbreaking advancements in cancer therapeutics and diagnostics. As of now, there is no public information available regarding the last investment and last investment investors.